Quest Diagnostics (DGX) Common Equity (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Common Equity data on file, last reported at $7.4 billion in Q1 2026.

• Quarterly Common Equity rose 5.8% year-over-year to $7.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 billion (up 5.8% YoY) and the FY2025 annual result came in at $7.2 billion, up 5.24% from the prior year.
• Common Equity climbed to $7.4 billion in Q1 2026 per DGX's latest filing, from $7.2 billion in the prior quarter.
• The five-year high for Common Equity was $7.4 billion in Q1 2026, with the low at $5.9 billion in Q4 2022.
• Average Common Equity over 5 years is $6.6 billion, with a median of $6.5 billion recorded in 2024.
• Year-over-year, Common Equity dropped 8.53% in 2022 and gained 9.15% in 2025.
• Quest Diagnostics' Common Equity stood at $5.9 billion in 2022, then gained by 6.95% to $6.3 billion in 2023, then grew by 7.43% to $6.8 billion in 2024, then grew by 5.24% to $7.2 billion in 2025, then advanced by 2.73% to $7.4 billion in 2026.
• Business Quant data shows DGX's Common Equity at $7.4 billion in Q1 2026, $7.2 billion in Q4 2025, and $7.3 billion in Q3 2025.